Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines
Molecular Therapy · 2026-09 · 34 (9) · 5284-5301
DOI: 10.1016/j.ymthe.2026.06.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-09. Verfasst von Marlene Fyrstenberg Laursen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Antigen-Presenting Cells, Recombinant Fusion Proteins, Malaria Vaccines, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: South-Eastern Norway Regional Health Authority, SINTEF Industry, Wellcome Trust.
Abstract (Originalsprache)
mRNA-lipid nanoparticle (LNP) and adenoviral delivery of vaccines have proven effective during the COVID-19 pandemic. Herein, we explored whether antigen-presenting cell (APC) targeting of antigens could further enhance the immunogenicity of these delivery formats. Experiments were performed in mouse models for malaria (Plasmodium falciparum reticulocyte-binding protein homolog 5 [PfRH5] antigen) and influenza (hemagglutinin [HA] antigen). We used genetic constructs encoding bivalent fusion proteins that target antigens to MHC class II (MHCII) molecules on professional APCs. We demonstrate that MHCII-targeted fusion proteins bound to professional APCs and that such APC-targeting increased antibody and T cell responses as well as protection against the influenza virus. The results suggest that the injected mRNA-LNP and adenoviral vectors resulted in the secretion of fusion proteins that targeted APCs. Employing the APC-targeting principle could enhance the efficiency of adenoviral and mRNA-LNP vaccines against a variety of diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway.
- Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.
- Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
- Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway. Electronic address: ranveig.braathen@medisin.uio.no.
Förderung
- South-Eastern Norway Regional Health Authority
- SINTEF Industry
- Wellcome Trust
- University of Oslo
- EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
- Research Council of Norway
Zitieren
APA
Laursen, M. F., Combes, F., Gudjonsson, A., Bjerkan, L., Parot, J., Tesfaye, D. Y., Pettersson, F. J., Molska, A., Visweswaran, G. R. R., Labbé, G. M., Draper, S. J., Borgos, S. E., Bogen, B., & Braathen, R. (2026). Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines. Molecular Therapy, 34(9), 5284-5301. https://doi.org/10.1016/j.ymthe.2026.06.034
Vancouver
Laursen MF, Combes F, Gudjonsson A, Bjerkan L, Parot J, Tesfaye DY, et al. Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines. Molecular Therapy. 2026;34(9):5284-5301. doi:10.1016/j.ymthe.2026.06.034
BibTeX
@article{Laursen2026,
author = {Laursen, Marlene Fyrstenberg and Combes, Francis and Gudjonsson, Arnar and Bjerkan, Louise and Parot, Jérémie and Tesfaye, Demo Yemane and Pettersson, Frida J and Molska, Alicja and Visweswaran, Ganesh Ram R and Labbé, Geneviève M and Draper, Simon J and Borgos, Sven Even and Bogen, Bjarne and Braathen, Ranveig},
title = {Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {9},
pages = {5284--5301},
doi = {10.1016/j.ymthe.2026.06.034}
}
EUVIMED